5-EAPB (1-(benzofuran-5-yl)-N-ethylpropan-2-amine) is an entactogenic amphetamine which is structurally related to 5-MAPB and 5-APB.

SKU: N/A Category:


5-EAPB (1-(benzofuran-5-yl)-N-ethylpropan-2-amine) is an entactogenic amphetamine which is structurally related to 5-MAPB and 5-APB. It might be predicted to show similar effects to these drugs in humans, but the pharmacology of 5-EAPB remains unstudied as of 2013.

5-EAPB is similar in structure to compounds such as 5-APB which are claimed to be agonists of the 5-HT2C receptor  as well as a triple monoamine reuptake inhibitors, however 5-EAPB is not listed as an example in this patent, and it is not yet established to what extent the activity of 5-EAPB resembles that of 5-APB.

As an N-ethyl derivative of 5-APB, 5-EAPB falls outside the scope of the Temporary Class Drug ban issued by the Home Office on June 10, 2013, and remains uncontrolled in the UK as of November 2013. The ACMD has advised that 5-EAPB (and other -APBs) are moved to Class B,[3] this will likely come into action on 10 June 2014.

5-EAPB is listed in the Fifth Schedule of the Misuse of Drugs Act (MDA) and therefore illegal in Singapore as of May 2015.

Methoxphenidine (also known as MXP) is a lesser-known novel dissociative substance of the diarylethylamine class that produces dissociative and hallucinogenic effects when administered. It is structurally related to diarylethylamines like diphenidine and ephenidine.

Methoxphenidine is classified as an NMDA receptor antagonist. Members of this class induce a state known as “dissociative anesthesia” and are used in both medical (e.g. surgical anesthesia) and recreational settings. These include arylcyclohexylamines like ketamine and phencyclidine (PCP), as well as dextromethorphan (DXM).

Methoxphenidine along with related diarylethylamines have been studied as treatments for neurotoxic injuries. It has no documented history of non-medical use before the 2013 UK arylcyclohexylamine ban, when it and diphenidine became available in powder and tablet form on the online research chemical market. It was initially marketed as a replacement for methoxetamine (MXE) although users report substantially different effects. It is an example of a designer drug specifically chosen to mimic the functional or structural features of commonly used illicit substances and circumvent government regulation.





There are no reviews yet.

Be the first to review “5-EAPB”

Your email address will not be published. Required fields are marked *